<p>根据 XTX Topco Ltd 最近向证券交易委员会提交的 13F 文件，该公司在第四季度减少了对诺华制药 (NYSE:NVS - 免费报告) 的持股 66.0%。在该季度出售了 20,140 股后，该公司持有 10,379 股诺华的股票。根据其最近向证券交易委员会的文件，XTX Topco Ltd 在诺华的持股价值为 1,010,000 美元。</p>
<ul>
<li>制药巨头盈利超预期，但股价下跌</li>
</ul>
<p>其他几家对冲基金也增加或减少了对该公司的投资。Raymond James Financial Inc.在第四季度购买了诺华的股份，投资额约为 88,339,000 美元。Renaissance Technologies LLC 在第四季度将其在诺华的持股增加了 16.0%。Renaissance Technologies LLC 目前持有 2,668,849 股诺华的股票，价值 259,706,000 美元，此前在该期间又购买了 368,171 股。Fisher Asset Management LLC 在第四季度将其在诺华的持股增加了 17.4%。Fisher Asset Management LLC 目前持有 2,002,959 股诺华的股票，价值 194,908,000 美元，此前在该期间又购买了 296,950 股。Mirae Asset Global Investments Co. Ltd.在第四季度将其在诺华的持股增加了 128.1%。Mirae Asset Global Investments Co. Ltd.目前持有 528,682 股诺华的股票，价值 51,554,000 美元，此前在上个季度又购买了 296,890 股。最后，Proficio Capital Partners LLC 在第四季度购买了诺华的新股份，投资额为 225,000 美元。13.12% 的股票由机构投资者持有。</p>
<h2>诺华股票上涨 0.3%</h2>
<p>周三，NYSE:NVS 的开盘价为 109.84 美元。该公司的债务与股本比率为 0.48，流动比率为 1.04，速动比率为 0.84。该公司的 50 日移动平均价格为 109.01 美元，200 日移动平均价格为 106.36 美元。该公司的市值为 2245.2 亿美元，市盈率为 18.68，市盈增长比率为 1.70，贝塔值为 0.56。诺华制药的 1 年最低价为 92.35 美元，1 年最高价为 120.92 美元。</p>
<ul>
<li>20 只最佳医疗保健分红股票投资指南</li>
</ul>
<p>诺华 (NYSE:NVS - 获取免费报告) 最近一次公布财报是在 1 月 31 日，报告每股收益为 1.98 美元，超出分析师一致预期的 1.80 美元，超出幅度为 0.18 美元。诺华的净利润率为 23.56%，股本回报率为 37.24%。分析师平均预测诺华制药在当前财年的每股收益为 8.45 美元。</p>
<h2>诺华分红公告</h2>
<p>该公司最近宣布了一项分红，已于 3 月 12 日支付。3 月 12 日的股东获得了 3.8695 美元的分红。除息日为 3 月 12 日。诺华的分红支付比率 (DPR) 为 42.69%。</p>
<h2>分析师评级变动</h2>
<ul>
<li>Voyager Therapeutics 股票因与诺华达成交易而上涨 30%</li>
</ul>
<p>NVS 最近受到几份分析师报告的关注。摩根士丹利在 2 月 12 日的研究报告中对诺华的股票进行了覆盖，给予了 “减持” 评级。瑞银集团在 2 月 13 日的研究报告中重申了对诺华的 “中性” 评级。StockNews.com 在 2 月 8 日的研究报告中将诺华的评级从 “买入” 上调至 “强力买入”。巴克莱在 2 月 3 日的报告中重申了对诺华的 “减持” 评级。最后，德意志银行在 2 月 4 日的报告中将诺华的评级从 “持有” 上调至 “买入”。三位投资分析师对该股票给予了卖出评级，六位给予了持有评级，一位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，平均目标价为 123.38 美元。</p>
<p><strong>阅读我们关于 NVS 的最新研究报告</strong></p>
<h2>关于诺华</h2>
<p>(免费报告)</p>
<p>诺华制药公司在瑞士及国际上从事医疗产品的研究、开发、生产和营销。该公司为患者和医生提供处方药。其重点领域包括心血管、肾脏和代谢、免疫学、神经科学和肿瘤学，以及眼科和血液学。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过诺华</li>
<li>什么是分红成就者？简介</li>
<li>小心 BigBear.ai：内部人士正在出售——你应该注意吗？</li>
<li>什么是便士股票？全面指南</li>
<li>CrowdStrike 股票在网络威胁环境扩大的情况下值得购买</li>
<li>什么是空头头寸？如何使用它</li>
<li>国会！在关税引发的崩溃中，谁交易了什么</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在诺华吗？</h2>
<p>在考虑诺华之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而诺华并不在名单上。</p>
<p>虽然诺华目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

诺华制药

<p>根据最近的 SEC 文件，XTX Topco Ltd 在第四季度将其在诺华制药（NYSE:NVS）的持股比例减少了 66%。在出售了 20,140 股后，现持有 10,379 股，价值约为 1,010,000 美元。其他对冲基金也调整了在诺华的持仓。该股票开盘价为 109.84 美元，市值为 2245.2 亿美元，市盈率为 18.68。诺华最近报告每股收益为 1.98 美元，超出预期，并宣布每股派息 3.8695 美元</p>

<p>XTX Topco Ltd lessened its holdings in Novartis AG (NYSE:NVS - Free Report) by 66.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 10,379 shares of the company's stock after selling 20,140 shares during the quarter. XTX Topco Ltd's holdings in Novartis were worth $1,010,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>根据 XTX Topco Ltd 最近向证券交易委员会提交的 13F 文件，该公司在第四季度减少了对诺华制药 (NYSE:NVS - 免费报告) 的持股 66.0%。在该季度出售了 20,140 股后，该公司持有 10,379 股诺华的股票。根据其最近向证券交易委员会的文件，XTX Topco Ltd 在诺华的持股价值为 1,010,000 美元。</p>
</div><ul>
<li>Pharma Leader Beats on Earnings, But Shares Fall</li>
</ul>
<div class="lb-trans"><ul>
<li>制药巨头盈利超预期，但股价下跌</li>
</ul>
</div><p>Several other hedge funds have also added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in shares of Novartis in the fourth quarter worth about $88,339,000. Renaissance Technologies LLC increased its stake in Novartis by 16.0% in the 4th quarter. Renaissance Technologies LLC now owns 2,668,849 shares of the company's stock worth $259,706,000 after purchasing an additional 368,171 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Novartis by 17.4% during the fourth quarter. Fisher Asset Management LLC now owns 2,002,959 shares of the company's stock valued at $194,908,000 after purchasing an additional 296,950 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Novartis by 128.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 528,682 shares of the company's stock worth $51,554,000 after purchasing an additional 296,890 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new stake in Novartis during the 4th quarter valued at $225,000. 13.12% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金也增加或减少了对该公司的投资。Raymond James Financial Inc.在第四季度购买了诺华的股份，投资额约为 88,339,000 美元。Renaissance Technologies LLC 在第四季度将其在诺华的持股增加了 16.0%。Renaissance Technologies LLC 目前持有 2,668,849 股诺华的股票，价值 259,706,000 美元，此前在该期间又购买了 368,171 股。Fisher Asset Management LLC 在第四季度将其在诺华的持股增加了 17.4%。Fisher Asset Management LLC 目前持有 2,002,959 股诺华的股票，价值 194,908,000 美元，此前在该期间又购买了 296,950 股。Mirae Asset Global Investments Co. Ltd.在第四季度将其在诺华的持股增加了 128.1%。Mirae Asset Global Investments Co. Ltd.目前持有 528,682 股诺华的股票，价值 51,554,000 美元，此前在上个季度又购买了 296,890 股。最后，Proficio Capital Partners LLC 在第四季度购买了诺华的新股份，投资额为 225,000 美元。13.12% 的股票由机构投资者持有。</p>
</div><h2>Novartis Stock Up 0.3 %</h2>
<div class="lb-trans"><h2>诺华股票上涨 0.3%</h2>
</div><p>NYSE:NVS opened at $109.84 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. The firm's 50-day moving average price is $109.01 and its 200-day moving average price is $106.36. The company has a market capitalization of $224.52 billion, a PE ratio of 18.68, a P/E/G ratio of 1.70 and a beta of 0.56. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92.</p>
<div class="lb-trans"><p>周三，NYSE:NVS 的开盘价为 109.84 美元。该公司的债务与股本比率为 0.48，流动比率为 1.04，速动比率为 0.84。该公司的 50 日移动平均价格为 109.01 美元，200 日移动平均价格为 106.36 美元。该公司的市值为 2245.2 亿美元，市盈率为 18.68，市盈增长比率为 1.70，贝塔值为 0.56。诺华制药的 1 年最低价为 92.35 美元，1 年最高价为 120.92 美元。</p>
</div><ul>
<li>20 best healthcare dividend stocks to invest in</li>
</ul>
<div class="lb-trans"><ul>
<li>20 只最佳医疗保健分红股票投资指南</li>
</ul>
</div><p>Novartis (NYSE:NVS - Get Free Report) last announced its earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, equities analysts predict that Novartis AG will post 8.45 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>诺华 (NYSE:NVS - 获取免费报告) 最近一次公布财报是在 1 月 31 日，报告每股收益为 1.98 美元，超出分析师一致预期的 1.80 美元，超出幅度为 0.18 美元。诺华的净利润率为 23.56%，股本回报率为 37.24%。分析师平均预测诺华制药在当前财年的每股收益为 8.45 美元。</p>
</div><h2>Novartis Dividend Announcement</h2>
<div class="lb-trans"><h2>诺华分红公告</h2>
</div><p>The business also recently announced a dividend, which was paid on Wednesday, March 12th. Shareholders of record on Wednesday, March 12th were issued a $3.8695 dividend. The ex-dividend date was Wednesday, March 12th. Novartis's dividend payout ratio (DPR) is 42.69%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项分红，已于 3 月 12 日支付。3 月 12 日的股东获得了 3.8695 美元的分红。除息日为 3 月 12 日。诺华的分红支付比率 (DPR) 为 42.69%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Voyager Therapeutics stock pops 30% on deal with Novartis</li>
</ul>
<div class="lb-trans"><ul>
<li>Voyager Therapeutics 股票因与诺华达成交易而上涨 30%</li>
</ul>
</div><p>NVS has been the subject of several recent analyst reports. Morgan Stanley assumed coverage on shares of Novartis in a research note on Wednesday, February 12th. They set an &#34;underweight&#34; rating for the company. UBS Group reiterated a &#34;neutral&#34; rating on shares of Novartis in a research report on Thursday, February 13th. StockNews.com raised Novartis from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, February 8th. Barclays reiterated an &#34;underweight&#34; rating on shares of Novartis in a report on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Tuesday, February 4th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of &#34;Hold&#34; and an average target price of $123.38.</p>
<div class="lb-trans"><p>NVS 最近受到几份分析师报告的关注。摩根士丹利在 2 月 12 日的研究报告中对诺华的股票进行了覆盖，给予了 “减持” 评级。瑞银集团在 2 月 13 日的研究报告中重申了对诺华的 “中性” 评级。StockNews.com 在 2 月 8 日的研究报告中将诺华的评级从 “买入” 上调至 “强力买入”。巴克莱在 2 月 3 日的报告中重申了对诺华的 “减持” 评级。最后，德意志银行在 2 月 4 日的报告中将诺华的评级从 “持有” 上调至 “买入”。三位投资分析师对该股票给予了卖出评级，六位给予了持有评级，一位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，平均目标价为 123.38 美元。</p>
</div><p><strong>Read Our Latest Research Report on NVS</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 NVS 的最新研究报告</strong></p>
</div><h2>About Novartis</h2>
<div class="lb-trans"><h2>关于诺华</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.</p>
<div class="lb-trans"><p>诺华制药公司在瑞士及国际上从事医疗产品的研究、开发、生产和营销。该公司为患者和医生提供处方药。其重点领域包括心血管、肾脏和代谢、免疫学、神经科学和肿瘤学，以及眼科和血液学。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Novartis</li>
<li>What Are Dividend Achievers? An Introduction</li>
<li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li>
<li>What is a penny stock? A comprehensive guide</li>
<li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li>
<li>What is Short Interest? How to Use It</li>
<li>Congress! Who Traded What During the Tariff-Induced Meltdown</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过诺华</li>
<li>什么是分红成就者？简介</li>
<li>小心 BigBear.ai：内部人士正在出售——你应该注意吗？</li>
<li>什么是便士股票？全面指南</li>
<li>CrowdStrike 股票在网络威胁环境扩大的情况下值得购买</li>
<li>什么是空头头寸？如何使用它</li>
<li>国会！在关税引发的崩溃中，谁交易了什么</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Novartis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在诺华吗？</h2>
</div><p>Before you consider Novartis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑诺华之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而诺华并不在名单上。</p>
</div><p>While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺华目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

XTX Topco Ltd 减少了其在诺华制药（NYSE:NVS）的持股